{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:28:39Z","timestamp":1789939719684,"version":"4.0.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.antiviral.2016.08.024","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T01:50:10Z","timestamp":1472867410000},"page":"58-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8477-1827","authenticated-orcid":false,"given":"Danielle","family":"El-Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"El Chaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-5248","authenticated-orcid":false,"given":"Jackapat","family":"Vanichanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimpy P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella J.","family":"Ariza-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Mulanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Gulbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.08.024_bib1","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in\u00a0vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.024_bib2","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2016.08.024_bib3","series-title":"Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir","author":"Chimerix Press Release","year":"2015"},{"key":"10.1016\/j.antiviral.2016.08.024_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CMR.12.2.286","article-title":"Resistance of human cytomegalovirus to antiviral drugs","volume":"12","author":"Erice","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2016.08.024_bib5","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1586\/14787210.2014.948847","article-title":"Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses","volume":"12","author":"Florescu","year":"2014","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2016.08.024_bib6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/AAC.49.3.873-883.2005","article-title":"Human cytomegalovirus resistance to antiviral drugs","volume":"49","author":"Gilbert","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.08.024_bib7","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antivir. Res."},{"issue":"Suppl.\u00a05","key":"10.1016\/j.antiviral.2016.08.024_bib8","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1086\/422364","article-title":"Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients","volume":"39","author":"Levin","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.08.024_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.08.024_bib10","doi-asserted-by":"crossref","first-page":"S273","DOI":"10.1016\/j.bbmt.2010.12.364","article-title":"Experience with CMX001, a novel antiviral drug, for cytomegalovirus infections in stem cell transplant patients","author":"Papanicolau","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2016.08.024_bib11","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1086\/656717","article-title":"Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies","volume":"202","author":"Quenelle","year":"2010","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.08.024_bib12","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in\u00a0vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216303953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216303953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T01:39:23Z","timestamp":1568338763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216303953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":12,"alternative-id":["S0166354216303953"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.08.024","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}